Family Pharmacy of Statesville, Inc., Statesville, NC
Is Family Pharmacy of Statesville, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Family Pharmacy of Statesville, Inc. hold a North Carolina pharmacy license?
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
Has Family Pharmacy of Statesville, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Nov 6, 2020) for Family Pharmacy of Statesville, Inc. State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Family Pharmacy of Statesville, Inc.
- Location
- Statesville, NC
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Mar 11, 2022
- FDA Data Dashboard inspections
- 0 inspections; 0 published Form 483s
- Form 483 text on this page
- 1 Form 483, 9 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Family Pharmacy of Statesville, Inc., a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Mar 11, 2022 | Form 483 | 483 Issued 03/11/2022 | FDA copy (archived) |
| Nov 6, 2020 | Warning letter | Warning Letter (11/06/2020) | FDA copy (archived) |
| Feb 12, 2020 | Form 483 | 483 Issued 02/12/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Family Pharmacy of Statesville, Statesville, NC (FEI number 3015859129), matched to this page by exact name, city and state. It lists no classified inspection under this name at that site. Dashboard firm profile.
Form 483s FDA has published for this site
No published Form 483 for FEI 3015859129 was found in the dashboard’s list of published 483s on Nov 15, 2026. FDA publishes only some 483s, so this does not mean none was issued.
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 9, 2022 to Mar 11, 2022: 9 observations
- Firm on the cover
- Family Pharmacy of Statesville, Inc., 3478 E. Broad St., Statesville, NC 28625
- FEI number
- 3015859129
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Your facility was operated in a way that permits poor flow of materials.
Specifically,
I I
A. During the compounding of Hydromorphone l mg/mL infusion lot #528, the pharmacy technician failed to wipe down the <Redacted B4> and the supplies with sterile <Redacted B4> prior to introduction into ISO 5 BSC.
B. Prior to and after compounding Hydromorphone 1 mg/mL infusion lot #528, the pharmacy technician failed to wipe down the sterile <Redacted B4> bottle prior to introduction into the ISO 5 BSC.
Observation 2
Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.
Specifically, the sporicidal agent, <Redacted B4> that your firm uses to clean the surfaces inside of the ISO 5 BSC requires a <Redacted B4> contact time. Your technician stated that this product is used on an <Redacted B4> <Redacted B4> basis and left on the inside surface of the ISO 5 BSC to dry while he performs cleaning of the outside surfaces of the BSC then does a final wipe down inside with sterile <Redacted B4>
AOcl Contlnuation Page
BSC then does a final wipe down inside with sterile ll>lt'1l
Observation 3
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worse case activities and conditions that provide a challenge to aseptic operations.
Specifically, the firm's <Redacted B4> media fill which mimics their high-risk infusion compound, Hydromorphone, was performed with <Redacted B4> IV bags of <Redacted B4> each for a total batch size of <Redacted B4>. However, the firm 's highest volume as seen on their <Redacted B4> batch log for this infusion compound is <Redacted B4>.
(REPEAT OBSERVATION)
Observation 4
You did not have a HEPA filter over the area to which sterile product was exposed without any information to support that the components remained sterile throughout the storage period.
Specifically, your firm states that the prescription laboratory room is classified as ISO 8 but there is no HEPA filter present. The <Redacted B4> glassware used in sterile processing are stored in this room.
Observation 5
The cycle parameters used for <Redacted B4> of materials used to prepare sterile injectable drug products were not verified using endotoxin indicators.
Add Continuation Page
Specifically, you do not use endotoxin indicators to ensure and verify that the temperature and time cycle used to sterilize and <Redacted B4> glassware is adequate.
(REPEAT OBSERVATION)
Observation 6
Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area.
Specifically,
A. According to our interview with the pharmacy technicians, no equipment or supplies were present in the ISO 5 BSC and they did not simulate the worst case scenario compounding activities during the smoke studies.
B. Your ISO 7 clean room was certified with both ISO 5 BSC turned on however, subsequent compounding and media fills were performed with <Redacted B4> hood running which could potentially impact the airflow.
Observation 7
Non-microbial contamination was observed in your production area.
Specifically, we observed what appeared to be rust inside the cabinet storing both hazardous bulk drug substances and hazardous chemicals. The bottom door hinges and the bottom shelf on this cabinet had visible rust shavings.
Observation 8
Your facility design allowed the influx of poor quality air into a higher classified area.
Specifically, the pressure between the ISO 8 anteroom and ISO 7 clean room is kept the same possibly leading to lower quality ISO 8 air entering ISO 7 clean room every time the door is opened.
Observation 9
The ISO-classified processing areas had difficult to clean equipment.
Specifically, your firm uses a non-cleanroom compliant metal folding chair in the ISO 7 cleanroom while working in the ISO 5 BSC.
Add Continuation Page
Linked 483s whose text is not shown
- Feb 12, 2020: FDA document 144804: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.